Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | MASP2 | O00187 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8567081 | 1.00 | SMYD3 (0.56) | SMYD3MTNR1AGAAMAPTBACE1 | |
| SCHEMBL30357995 | 1.00 | SMYD3 (0.56) | SMYD3MTNR1AGAAMAPTBACE1 | |
| SCHEMBL926907 | 1.00 | SMYD3 (0.56) | SMYD3MTNR1AGAAMAPTBACE1 | |
| Hydrochloric Acid SCHEMBL5424922 | 0.98 | SMYD3 (0.54) | SMYD3MTNR1AGAAMAPTBACE1 | |
| SCHEMBL644461 | 0.84 | GAA (0.65) | SMYD3MTNR1AGAAMAPTBACE1 | |
| SCHEMBL926891 | 0.84 | GAA (0.65) | SMYD3MTNR1AGAAMAPTBACE1 | |
| SCHEMBL3989086 | 0.84 | GAA (0.65) | SMYD3MTNR1AGAAMAPTBACE1 | |
| SCHEMBL29569853 | 0.84 | GAA (0.65) | SMYD3MTNR1AGAAMAPTBACE1 | |
| SCHEMBL428189 | 0.84 | MTNR1A (0.53) | SMYD3MTNR1AGAAMAPTHTR1A | |
| SCHEMBL30358033 | 0.84 | MTNR1A (0.53) | SMYD3MTNR1AGAAMAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| CN-1041932-C | Tricyclic quinoxalinedione derivatives | SUMITOMO PHARMA (JP) | 1999-02-03 | — | — | CN | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5644055-A | Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ACE | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0706525-A1 | ANTIHYPERTENSIVE TRICYCLIC AZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | Novartis AG (CH) | 1996-04-17 | — | — | EP | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
| CN-1098722-A | Tricyclic quinoxalinedione derivatives | SUMITOMO PHARMA (JP) | 1995-02-15 | — | — | CN | disclosed |
| WO-1995001353-A1 | ANTIHYPERTENSIVE TRICYCLIC AZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | CIBA-GEIGY AG (CH) | 1995-01-12 | — | — | WO | disclosed |
| US-4401818-A | HYPOTENSIVE AGENTS, CARDIOACTIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | SMYD3 1251/4885MTNR1A 256/4885GAA 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.